PRX-14040

PRX-14040
Clinical data
Other namesPRX14040
Drug classDopamine reuptake inhibitor; Pro-motivational agent
Identifiers
  • 5-(2-(1-(3,4-dichlorophenyl)cyclobutyl)-2-hydroxyethyl)-2-oxa-5-azoniabicyclo[2.2.1]heptane chloride
CAS Number
PubChem CID
Chemical and physical data
FormulaC17H22Cl3NO2
Molar mass378.72 g·mol−1
3D model (JSmol)
  • C1CC(C1)(C2=CC(=C(C=C2)Cl)Cl)C(C[NH+]3CC4CC3CO4)O.[Cl-]
  • InChI=1S/C17H21Cl2NO2.ClH/c18-14-3-2-11(6-15(14)19)17(4-1-5-17)16(21)9-20-8-13-7-12(20)10-22-13;/h2-3,6,12-13,16,21H,1,4-5,7-10H2;1H
  • Key:QAHXUHUHCQYFHC-UHFFFAOYSA-N

PRX-14040 is a selective dopamine reuptake inhibitor that was developed by Prexa Pharmaceuticals. It has 28-fold selectivity for the dopamine transporter over the norepinephrine transporter. Similarly to various other dopamine reuptake inhibitors, the drug has been found to reverse motivational deficits induced by the dopamine depleting agent tetrabenazine in animals.

See also

References

  1. 1 2 Salamone JD, Correa M, Ferrigno S, Yang JH, Rotolo RA, Presby RE (October 2018). "The Psychopharmacology of Effort-Related Decision Making: Dopamine, Adenosine, and Insights into the Neurochemistry of Motivation". Pharmacol Rev. 70 (4): 747–762. doi:10.1124/pr.117.015107. PMC 6169368. PMID 30209181.
  2. 1 2 3 Desibhatla, Mukund (16 June 2021). "The Development and Evaluation of Novel DA Transport Inhibitors and their Effects on Effort-Related Motivation: A Review". Honors Scholar Theses. Retrieved 10 August 2024.
  3. ↑ Yohn SE, Gogoj A, Haque A, Lopez-Cruz L, Haley A, Huxley P, Baskin P, Correa M, Salamone JD (September 2016). "Evaluation of the effort-related motivational effects of the novel dopamine uptake inhibitor PRX-14040". Pharmacol Biochem Behav. 148: 84–91. doi:10.1016/j.pbb.2016.06.004. PMID 27296079.